Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The study met its primary endpoint and all 11 secondary efficacy endpoints
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
The launch of the study was on the occasion of the International Day of Persons with Disabilities
76 of 180 long COVID-associated genes also linked to ME
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated
